Erratum to: Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study (Diabetes Therapy, (2018), 10.1007/s13300-018-0378-4)

Abstract

In the original publication, values of the doses of insulin glargine, the most commonly used basal insulin analogue under the ‘Discussion’ section was incorrectly published. The sentence ‘‘…was similar (3100.314 ± 110.1298 U/kg body weight/day at baseline) to that in the Swedish study (0.33 ± 0.16 U/kg body weight/day)’’. Should actually say ‘‘…was similar (0.31 ± 0.12 U/kg body weight/day at baseline) to that in the Swedish study (0.33 ± 0.16 U/kg body weight/day)’’. Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. © 2018, The Author(s).